Lonza welcomes new CEO Wolfgang Wienand

1 July 2024

Wolfgang Wienand today joined Swiss contract development and manufacturing organization (CDMO) Lonza (VTX: LONN) as chief executive (CEO).

Mr Wienand succeeds Albert Baehny, who took on the role of CEO ad interim in October 2023 and was chairman of the board of directors of Lonza from 2018 to May 2024. Mr Baehny will work with Mr Wienand to ensure a smooth leadership handover before he retires from Lonza this summer.

“On behalf of the board, I extend a warm welcome to Wolfgang as he joins Lonza. Wolfgang brings with him a wealth of CDMO experience, combined with deep strategic and scientific expertise. As Wolfgang joins, we look forward to an era of stable and structured growth under his leadership,” commented Lonza Chairman Jean-Marc Huet.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK